Clinical trial
A Dose Escalation Study to Assess the Safety and Ability of SG1002 to Overcome Circulating Deficits in Hydrogen Sulfide Found in Heart Failure Patients
NCT01989208 is registered in ClinicalTrials.gov with Sulfagenix Australia Pty Ltd. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Dose Escalation Study to Assess the Safety and Ability of SG1002 to Overcome Circulating Deficits in Hydrogen Sulfide Found in Heart Failure Patients
- Lead sponsor
- Sulfagenix Australia Pty Ltd.
- Phase
- Not applicable
- Overall status
- Completed
- Start date
- January 31, 2014
- Completion date
- December 31, 2014
- Enrollment
- 16 (actual)
- Sites
- 2
Conditions
As the registry lists them; a condition with its own page is linked.